New NNT→Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. https://t.co/6OlJufnch4
RT @rincondesisifo: (2 minute medicine) El pre y post tratamiento con antiagregantes inhibidores de la P2Y12 en pac con SCASEST no provoca…
RT @rincondesisifo: (2 minute medicine) El pre y post tratamiento con antiagregantes inhibidores de la P2Y12 en pac con SCASEST no provoca…
RT @rincondesisifo: (2 minute medicine) El pre y post tratamiento con antiagregantes inhibidores de la P2Y12 en pac con SCASEST no provoca…
RT @rincondesisifo: (2 minute medicine) El pre y post tratamiento con antiagregantes inhibidores de la P2Y12 en pac con SCASEST no provoca…
RT @rincondesisifo: (2 minute medicine) El pre y post tratamiento con antiagregantes inhibidores de la P2Y12 en pac con SCASEST no provoca…
(2 minute medicine) El pre y post tratamiento con antiagregantes inhibidores de la P2Y12 en pac con SCASEST no provoca diferencias significativas en los resultados https://t.co/p4fZfiBpdy REC de ECA https://t.co/AfajJU5pos Estudio original https://t.co/lf
RT @giuseppe_ando: New data about pre-treatment #ESC2020 great collaborative work by @sicigise @giuseppemusum11 @espogiov @SABOURETCardio @…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @jpcostabel: Estudio DUBIUS, terminado prematuramente por poca difer de eventos ➡️Pretratamiento (tica) vs tratamiento en sala (Tica vs…
Estudio DUBIUS, terminado prematuramente por poca difer de eventos ➡️Pretratamiento (tica) vs tratamiento en sala (Tica vs Prasu) ➡️Punto final primario (isq + hemor RAR -0.46 [-2.90; 1.90]). ➡️Pocos eventos. 🤔Si es lo mismo, vamos sin pretratamiento? htt
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
Timing of Oral P2Y12 Inhibitor Administration in Non-ST Elevation Acute Coronary Syndrome https://t.co/LsQHENxccr
RT @thiele_holger: Nice to see that our guideline recommendation is correct. Accoast und Scaar registry as well as ISAR-REACT 5 all showed…
RT @thiele_holger: Nice to see that our guideline recommendation is correct. Accoast und Scaar registry as well as ISAR-REACT 5 all showed…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @thiele_holger: Nice to see that our guideline recommendation is correct. Accoast und Scaar registry as well as ISAR-REACT 5 all showed…
RT @thiele_holger: Nice to see that our guideline recommendation is correct. Accoast und Scaar registry as well as ISAR-REACT 5 all showed…
RT @thiele_holger: Nice to see that our guideline recommendation is correct. Accoast und Scaar registry as well as ISAR-REACT 5 all showed…
RT @vass_vassiliou: P2Y12 inhibitors in NSTEMI... upstream or downstream? Or dies it matter? Well probably it doesn’t matter according to t…
RT @thiele_holger: Nice to see that our guideline recommendation is correct. Accoast und Scaar registry as well as ISAR-REACT 5 all showed…
RT @thiele_holger: Nice to see that our guideline recommendation is correct. Accoast und Scaar registry as well as ISAR-REACT 5 all showed…
RT @thiele_holger: Nice to see that our guideline recommendation is correct. Accoast und Scaar registry as well as ISAR-REACT 5 all showed…
RT @thiele_holger: Nice to see that our guideline recommendation is correct. Accoast und Scaar registry as well as ISAR-REACT 5 all showed…
RT @thiele_holger: Nice to see that our guideline recommendation is correct. Accoast und Scaar registry as well as ISAR-REACT 5 all showed…
Nice to see that our guideline recommendation is correct. Accoast und Scaar registry as well as ISAR-REACT 5 all showed no benefit of pretreatment
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @FabioLimaMD: Hot off the press, just accepted to JACC: no ischemic or bleeding difference in upstream or downstream timing for prasugre…
Hot off the press, just accepted to JACC: no ischemic or bleeding difference in upstream or downstream timing for prasugrel or ticagreloe in NSTEMIs. Further evidence to support the new European guidelines. @ACCinTouch @escardio
RT @vass_vassiliou: P2Y12 inhibitors in NSTEMI... upstream or downstream? Or dies it matter? Well probably it doesn’t matter according to t…
RT @SABOURETCardio: #DAPT Timing of #DAPT in #NSTEMI . #cardiotwitter
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DFCapodanno: I recorded my #ESCCongress presentation on pretreatment weeks ago but since then the field has changed twice: with the NST…
RT @vass_vassiliou: P2Y12 inhibitors in NSTEMI... upstream or downstream? Or dies it matter? Well probably it doesn’t matter according to t…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DFCapodanno: I recorded my #ESCCongress presentation on pretreatment weeks ago but since then the field has changed twice: with the NST…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @giuseppe_ando: New data about pre-treatment #ESC2020 great collaborative work by @sicigise @giuseppemusum11 @espogiov @SABOURETCardio @…
RT @AriVinasMD: Timing of Oral P2Y12 Inhibitor Administration in Non-ST Elevation Acute Coronary Syndrome | JACC: Journal of the American C…
RT @DFCapodanno: I recorded my #ESCCongress presentation on pretreatment weeks ago but since then the field has changed twice: with the NST…
RT @giuseppe_ando: New data about pre-treatment #ESC2020 great collaborative work by @sicigise @giuseppemusum11 @espogiov @SABOURETCardio @…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @vass_vassiliou: P2Y12 inhibitors in NSTEMI... upstream or downstream? Or dies it matter? Well probably it doesn’t matter according to t…
RT @vass_vassiliou: P2Y12 inhibitors in NSTEMI... upstream or downstream? Or dies it matter? Well probably it doesn’t matter according to t…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @vass_vassiliou: P2Y12 inhibitors in NSTEMI... upstream or downstream? Or dies it matter? Well probably it doesn’t matter according to t…
RT @vass_vassiliou: P2Y12 inhibitors in NSTEMI... upstream or downstream? Or dies it matter? Well probably it doesn’t matter according to t…
RT @vass_vassiliou: P2Y12 inhibitors in NSTEMI... upstream or downstream? Or dies it matter? Well probably it doesn’t matter according to t…
RT @vass_vassiliou: P2Y12 inhibitors in NSTEMI... upstream or downstream? Or dies it matter? Well probably it doesn’t matter according to t…
RT @vass_vassiliou: P2Y12 inhibitors in NSTEMI... upstream or downstream? Or dies it matter? Well probably it doesn’t matter according to t…
RT @vass_vassiliou: P2Y12 inhibitors in NSTEMI... upstream or downstream? Or dies it matter? Well probably it doesn’t matter according to t…
RT @vass_vassiliou: P2Y12 inhibitors in NSTEMI... upstream or downstream? Or dies it matter? Well probably it doesn’t matter according to t…
P2Y12 inhibitors in NSTEMI... upstream or downstream? Or dies it matter? Well probably it doesn’t matter according to this @JACCJournals paper. Could potentially open up choice!https://t.co/mjFDROKaLR #ESCCongress #cardioed #EPeeps #radialfirst #echofirst
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
More data about pretreatment in #NSTEMI Timing of Oral P2Y12 Inhibitor Administration in Non-ST Elevation Acute Coronary Syndrome https://t.co/E2q2Qz5K6m
RT @GargiuloG83: Important ITALIAN 🇮🇹 trial showing no further DUBIUS about need for pretreatment in NSTEACS supporting new ESC guidelines.…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @giuseppe_ando: New data about pre-treatment #ESC2020 great collaborative work by @sicigise @giuseppemusum11 @espogiov @SABOURETCardio @…
RT @DFCapodanno: I recorded my #ESCCongress presentation on pretreatment weeks ago but since then the field has changed twice: with the NST…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @KardiologieHH: @AGIKinterv
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
#ESCCongress #ESCCongress2020 @escardio el final de precargar con inhibidor P2Y12 en SCA. Recomendación de las nuevas guías. Ahora más evidencia en NST. https://t.co/1lpOs0FFOH
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
@AGIKinterv
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
RT @DLBHATTMD: No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in No…
No apparent benefit to pretreatment - @escardio guidelines got it right! Timing of Oral P2Y12 Inhibitor Administration in Non-ST Elevation Acute Coronary Syndrome https://t.co/T7leOFW2rT #cardiology #cardiotwitter #PCI @ESC_Journals @thiele_holger @ColletJ
RT @DFCapodanno: I recorded my #ESCCongress presentation on pretreatment weeks ago but since then the field has changed twice: with the NST…
RT @giuseppe_ando: New data about pre-treatment #ESC2020 great collaborative work by @sicigise @giuseppemusum11 @espogiov @SABOURETCardio @…
Timing of Oral P2Y12 Inhibitor Administration in Non-ST Elevation Acute Coronary Syndrome | JACC: Journal of the American College of Cardiology https://t.co/lg0rRZMzKn
I always applaud RCTs of practice conundrums but I don't really know what to make of this study: https://t.co/Veb80pVhim
RT @GargiuloG83: Important ITALIAN 🇮🇹 trial showing no further DUBIUS about need for pretreatment in NSTEACS supporting new ESC guidelines.…
RT @giuseppe_ando: New data about pre-treatment #ESC2020 great collaborative work by @sicigise @giuseppemusum11 @espogiov @SABOURETCardio @…
DUBIUS Trial. To Pre-Treat or not Pre-Treat. Timing of Oral P2Y12 Inhibitor Administration in Non-ST Elevation Acute Coronary Syndrome https://t.co/fcaWP1XAWx
RT @DFCapodanno: I recorded my #ESCCongress presentation on pretreatment weeks ago but since then the field has changed twice: with the NST…
RT @DFCapodanno: I recorded my #ESCCongress presentation on pretreatment weeks ago but since then the field has changed twice: with the NST…
RT @giuseppe_ando: New data about pre-treatment #ESC2020 great collaborative work by @sicigise @giuseppemusum11 @espogiov @SABOURETCardio @…